(HealthDay) – Hydroxychloroquine is not beneficial for adults hospitalized with COVID-19. This comes from the formal completion of a study funded by the United States Institute of Heart, Lung, and Blood (NHLBI) and published online November 9 in the Journal of the American Medical Association.

Wesley H. Self, MD, MPH of Vanderbilt University Medical Center in Nashville, Tennessee, and colleagues examined whether hydroxychloroquine was hospitalized for adults with COVID-19 in a multicenter, randomized study conducted in 34 US hospitals is effective. Patients were randomly assigned to either hydroxychloroquine or placebo (242 and 237 patients, respectively); The process was terminated at the fourth interim analysis due to futility.

Of the patients, 90.4 percent completed the primary outcome assessment after 14 days. The researchers found that the clinical status on the ordinal score scale after 14 days did not differ significantly between the hydroxychloroquine and placebo groups (median 6 versus 6; adjusted odds ratio 1.02; 95 percent confidence interval 0.73 to 1.42). There was no significant difference between the groups for any of the 12 secondary endpoints. 28 days after randomization, 10.4 and 10.6 percent of the patients in the hydroxychloroquine and placebo groups died (absolute difference: -0.2 percent) [95 percent confidence interval, −5.7 to 5.3 percent];; adjusted odds ratio 1.07 [95 percent confidence interval, 0.54 to 2.09]).

“A rigorously designed clinical trial that captured patient-centered, clinically meaningful results was critical to reaching the firm conclusions about hydroxychloroquine use in COVID-19. ORCHID [Outcomes Related to COVID-19 Treated With Hydroxychloroquine Among Inpatients With Symptomatic Disease] shows that hydroxychloroquine does not improve clinical outcomes in hospitalized COVID-19 patients, “James P. Kiley, Ph.D., director of the division of lung diseases at the NHLBI, said in a statement.

Several authors have disclosed financial relationships with the biopharmaceutical industry.

Follow the latest news on the Coronavirus (COVID-19) outbreak

More information:
Abstract / full text


Copyright © 2020 HealthDay. All rights reserved.

Quote: NHLBI study does not come to a conclusion for hydroxychloroquine in COVID-19 (2020, November 12th), accessed on November 12th, 2020 from https://medicalxpress.com/news/2020-11-nhlbi-trial-benefit-hydroxychloroquine -covid-.html

This document is subject to copyright. Except for fair trade for the purpose of private study or research, no part may be reproduced without written permission. The content is provided for informational purposes only.